Login / Signup

Induction of ADCC by a folic acid-mAb conjugate prepared by tryptophan-selective reaction toward folate-receptor-positive cancer cells.

Hiroshi TagawaKatsuya MaruyamaKoichi SasakiNatsuki KonoueAkihiro KishimuraMotomu KanaiTakeshi MoriKounosuke OisakiYoshiki Katayama
Published in: RSC advances (2020)
We developed conjugates between monoclonal antibody (mAb) and folic acid (FA) by using a tryptophan (Trp)-selective reaction, which yields relatively homogenous products compared to conventional methods. The obtained mAb-FA conjugates showed significant cellular cytotoxicity toward folate receptor-expressing cancer cells, demonstrating that the conjugates retained the Fc region's original function.
Keyphrases
  • monoclonal antibody
  • cancer therapy
  • drug delivery
  • electron transfer
  • wild type